SCHEMBL30518034

SCHEMBL30518034

CC(=O)N[C@@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](Cc1ccccc1)C(=O)NCC(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCCN)C(=O)O

nearest known ligand 0.64

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ IL23R Q5VWK5 1/20 0.64
▸ MC4R P32245 2/20 0.63
▸ MC5R P33032 2/20 0.63
▸ MC3R P41968 2/20 0.63
▸ MC1R Q01726 2/20 0.63
▸ C5AR1 P21730 2/20 0.62
▸ CXCR4 P61073 7/20 0.61
▸ OPRM1 P35372 4/20 0.56
▸ OPRK1 P41145 4/20 0.56
▸ CTSL P07711 3/20 0.55
▸ CTSS P25774 3/20 0.55
▸ CTSK P43235 3/20 0.55
▸ CTSH P09668 1/20 0.55
▸ CXCL8 P10145 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31105508 0.97 IL23R (0.67) IL23RMC4RMC5RMC3RMC1R
SCHEMBL31105433 0.90 IL23R (0.69) IL23RMC4RMC5RMC3RMC1R
SCHEMBL29853539 0.90 C5AR1 (0.62) IL23RMC4RMC5RMC3RMC1R
SCHEMBL13144891 0.90 KISS1R (0.58) IL23RMC4RMC5RMC3RMC1R
SCHEMBL30518167 0.89 C5AR1 (0.69) IL23RMC4RMC5RMC3RMC1R
SCHEMBL30867019 0.88 CXCR4 (0.61) IL23RMC4RMC5RMC3RMC1R
SCHEMBL17642339 0.88 CTSL (0.57) IL23RCXCR4CTSLCTSSCTSK
SCHEMBL30518104 0.88 IL23R (0.63) IL23RMC4R
SCHEMBL31187042 0.88 CXCR4 (0.63) IL23RMC4RMC5RMC3RMC1R
SCHEMBL30518171 0.88 IL23R (0.63) IL23RMC4RMC5RMC3RMC1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260078144-A1 ACTIVE PEPTIDE, AND COMPOSITION AND USE THEREOF WINKEY TECH USA INC (US) 2026-03-19 — — US claimed
WO-2024217503-A1 ACTIVE PEPTIDE, AND COMPOSITION AND USE THEREOF 深圳市维琪科技股份有限公司 2024-10-24 — — WO claimed
CN-116535463-A Active peptide, composition and use thereof 深圳市维琪科技股份有限公司 2023-08-04 — — CN claimed
US-20260078144-A1 ACTIVE PEPTIDE, AND COMPOSITION AND USE THEREOF WINKEY TECH USA INC (US) 2026-03-19 — — US disclosed
WO-2024217503-A1 ACTIVE PEPTIDE, AND COMPOSITION AND USE THEREOF 深圳市维琪科技股份有限公司 2024-10-24 — — WO disclosed
CN-117343140-B Active peptide, composition and use thereof 深圳市维琪科技股份有限公司 2024-09-20 — — CN disclosed
CN-117343140-A Active peptide, composition and use thereof 深圳市维琪科技股份有限公司 2024-01-05 — — CN disclosed
CN-116535463-B Active peptide, composition and use thereof 深圳市维琪科技股份有限公司 2023-10-31 — — CN disclosed
CN-116535463-A Active peptide, composition and use thereof 深圳市维琪科技股份有限公司 2023-08-04 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260078144-A1 ACTIVE PEPTIDE, AND COMPOSITION AND USE THEREOF ARGLU1, ARG1, POT1 IL23R 4196/4885MC4R 72/4885MC5R 114/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback